A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
A phase 2 trial of 120 mg LY2784544 in myeloproliferative neoplasms, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms is a phase 2 interventional study registered as NCT01594723 by Eli Lilly and Company, with 110 participants enrolled, started 2012-05-22 and due to reach its primary completion in 2015-03-20. Interventions recorded: 120 mg LY2784544.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess SLN124 in Patients With Polycythemia Vera
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialStudy of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialINTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Eli Lilly (incl. Loxo) and the tag pipeline.